ISRCTN Registry API

curl 'https://www.isrctn.com/api/query/format/who?q=cancer&limit=1'

const res = await fetch("https://www.isrctn.com/api/query/format/who?q=cancer&limit=1");
if (!res.ok) throw new Error(`Request failed: ${res.status}`);
const data = await res.json();
console.log(data);

import requests

res = requests.get("https://www.isrctn.com/api/query/format/who?q=cancer&limit=1", timeout=20)
res.raise_for_status()
print(res.json())

<trials><trial>
  <main>
    <trial_id>ISRCTN99067257</trial_id>
    <utrn/>
    <reg_name>ISRCTN</reg_name>
    <date_registration>20/08/2026</date_registration>
    <primary_sponsor>University of Leeds</primary_sponsor>
    <public_title>REASCENT trial: a proof of principle trial to treat active systemic sclerosis via interferon inhibition</public_title>
    <acronym>REASCENT</acronym>
    <scientific_title>REASCENT trial: a proof of principle trial to treat active systemic sclerosis via interferon inhibition</scientific_title>
    <date_enrolment>27/09/2025</date_enrolment>
    <type_enrolment>Actual</type_enrolment>
    <target_size>35</target_size>
    <recruitment_status>Recruiting</recruitment_status>
    <url>https://www.isrctn.com/ISRCTN99067257</url>
    <study_type>Interventional</study_type>
    <study_design>Interventional randomized controlled trial (Safety)</study_design>
    <phase>Phase II</phase>
    <hc_freetext>Systemic sclerosis</hc_freetext>
    <i_freetext>This is a single-arm, open-label, proof-of-principle trial to evaluate the safety and tolerability of an intravenous (IV) treatment regimen of anifrolumab 300 mg in patients with active systemic sclerosis (SSc) while receiving standard of care (SOC) treatment. Participants enrolled in REASCENT will receive a fixed intravenous dose of anifrolumab 300 mg every 4 weeks (Q4W) for a total of 13 doses (Week 0 to Week 48).</i_freetext>
    <results_actual_enrolment>0</results_actual_enrolment>
    <results_date_completed>31/08/2028</results_date_completed>
    <results_url_link/>
    <results_summary/>